Equities

Protext Mobility Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TXTM:PKC

Protext Mobility Inc

Actions
TechnologyTechnology
  • Price (USD)0.0048
  • Today's Change0.001 / 11.63%
  • Shares traded13.97m
  • 1 Year change+433.33%
  • Beta-2.9700
Data delayed at least 15 minutes, as of Feb 10 2026 15:58 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Protext Mobility, Inc. is a biotech company developing a hemp/cannabidiol (CBD) - cannabis medicines platform for the legal cannabis industry, using live plant extraction processes and technologies. The Company engages in the research, testing and development of bioavailable botanical products all-natural ingredients formulated for nutraceutical and pharmaceutical applications using proprietary live plant extraction technology. The Company's subsidiaries include Plandai Biotechnology, Cannabis Biosciences, Inc., and RSAMMD Acquisitions LLC.

  • Revenue in USD (TTM)750.00
  • Net income in USD-2.21m
  • Incorporated2010
  • Employees4.00
  • Location
    Protext Mobility Inc1100 Brickell Bay Drive 310747MIAMI 33231United StatesUSA
  • Phone+1 (516) 802-0223
  • Fax+1 (302) 655-5049
  • Websitehttp://ww1.protextm.co/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Onkure Therapeutics Inc0.00-81.21m34.68m46.00--0.5221-----12.78-12.780.004.900.00----0.00-107.93-48.73-115.20-53.34------------0.00------31.94--49.34--
Tvardi Therapeutics Inc4.02m-13.95m35.84m10.00--1.29--8.91-8.36-8.360.77092.970.0891----402,400.00-30.87-36.79-40.26-41.45100.00---346.55-155.60----0.00---65.96-18.5340.20--125.35--
Actinium Pharmaceuticals Inc90.00k-34.60m35.88m37.00--2.60--398.61-1.11-1.110.00290.44190.0013----2,432.43-50.05-43.20-55.95-47.84-----38,443.33-7,408.74----0.0009---100.00--21.66---29.66--
Atara Biotherapeutics Inc151.93m23.40m35.91m38.002.27--1.350.23632.192.1912.81-5.081.763.9993.55993,006.6027.07-67.79---93.0781.63--15.40-558.471.0215.248.31--1,404.02--69.07---46.73--
Axe Compute Inc728.20k-84.01m36.36m23.00------49.94-120.02-120.661.29-100.940.13691.342.9731,660.87-1,579.84-85.09---113.4250.2461.31-11,536.93-1,267.270.0134-0.1392-----0.23842.849.63---18.60--
PDS Biotechnology Corp0.00-34.88m36.59m24.00--3.53-----0.8194-0.81940.000.19820.00----0.00-80.05-57.93-125.74-68.38-----------8.430.6552------12.42------
Xilio Therapeutics Inc31.80m-58.49m36.86m64.00------1.16-0.6571-0.65710.3348-0.15620.3053----496,937.50-56.14-67.88-102.68-81.71-----183.90-5,578.28---2.84--------23.77---45.00--
Protext Mobility Inc750.00-2.21m37.80m4.00------50,403.00-0.4692-0.46920.00001-0.01020.0405-------9,400.97-1,587.94----86.67-530.19-232,392.00-17,498.830.0002-1.36-----93.98-63.0927.35------
Jasper Therapeutics Inc0.00-91.02m38.06m64.00--3.29-----5.90-5.900.000.41350.00----0.00-116.04-75.11-147.54-86.11------------0.00-------10.55------
Galecto Inc0.00-15.84m38.28m5.00--4.78-----12.01-12.010.006.030.00----0.00-92.89-47.05-109.09-50.67------------0.00------44.10------
Veru Inc0.00-15.68m38.36m20.00--1.91-----1.07-1.550.001.250.00----0.00-34.75-47.51-44.42-59.79-------188.81----0.00------55.53---60.02--
Cypherpunk Technologies Inc0.00-50.81m38.53m52.00--10.46-----1.23-1.230.000.0650.00----0.00-132.94-79.03-196.76-93.29-------9,055.53----0.00------16.74------
Liminatus Pharma Inc0.00-2.27m39.24m-----------0.0872-0.08720.00-0.06080.00-------77.46-----------------12.30--------28.85------
Lisata Therapeutics Inc1.07m-18.24m40.13m26.00--2.29--37.51-2.13-2.130.12461.980.0357----41,153.85-60.85-44.77-71.25-49.07-----1,704.86-13,065.70----0.00------4.10------
INmune Bio Inc50.00k-49.89m40.94m22.00--1.61--818.83-2.14-2.140.00210.95460.0012--0.02582,272.73-115.83-45.54-153.59-52.16-----99,774.00-19,298.45---942.220.00---90.97---40.24------
Data as of Feb 10 2026. Currency figures normalised to Protext Mobility Inc's reporting currency: US Dollar USD
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.